The Checkup by Singlecare
MARCH 7, 2024
Yet the Food and Drug Administration (FDA) hasn’t approved this GLP-1 agonist injection for weight loss. Instead, it’s FDA approved to improve glycemic control in adults with Type 2 diabetes and to reduce the risk of adverse cardiovascular events in adults with Type 2 diabetes and known heart disease.
The Checkup by Singlecare
APRIL 17, 2024
Legislation passed in 2003 prohibits Medicare from covering drugs prescribed specifically for weight loss, and while Medicaid has more flexibility here, not every state will cover them. Look into compounded options (but be careful). Mounjaro’s only on-label use is for diabetes, so Medicaid likely won’t cover it for obesity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 2, 2022
The term ‘psychedelic treatments’ incorporates a broad spectrum of different compounds, from LSD, psilocybin and DMT, to MDMA, ibogaine and ketamine. The latter compound has already been approved for treatment-resistance depression as the product Spravato (esketamine), after being developed by Janssen.
The Checkup by Singlecare
MARCH 21, 2024
A 2003 law prohibits government-sponsored plans like Medicare from covering weight loss medication. Consider a compounded version For drugs on the Food and Drug Administration (FDA) shortage list, compounding pharmacies can create and sell copies, often at lower prices than the brand-name versions.
ISPE
APRIL 13, 2023
1 More recently, regulators like the FDA have increasingly promoted the benefits of modeling (e.g., Topics in Chemical Engineering, 2003. Biopharma Adopts Mechanistic Modeling Mechanistic modeling has been widely used in the petrochemical industry for many decades, while biochemical producers have been slower to adopt. Melton, and E.
The Checkup by Singlecare
FEBRUARY 6, 2024
Food and Drug Administration (FDA). Since atomoxetine treats attention-deficit hyperactivity disorder by being a selective norepinephrine reuptake inhibitor and since norepinephrine is an adrenaline compound, MAOIs are hazardous if taken concurrently or within 14 days of atomoxetine. MAOIs can lead to an increase in adrenaline.
ISPE
NOVEMBER 2, 2022
Those began 20 years ago when he was involved in a major FDA inspection by Robert Tollefsen and Thomas Arista that significantly changed computer system validation in the industry. “As As a result, I was asked to present learning points and outcomes of that inspection at a GAMP Forum in San Francisco in January 2003.
Expert insights. Personalized for you.
93 
Let's personalize your content